Highly Galactosylated Anti-TNF (Infliximab) Antibody (CAT#: BioBet-GA-021ZP) Datasheet

TNF

tumor necrosis factor

This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine.

DIF; TNFA; TNFSF2; TNLG1F; TNF-alpha

Plasma membrane, Extracellular region or secreted

Its related pathways are Apoptosis Modulation and Signaling and Monoamine Transport.

1.Cytokines that bind to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can cause cell death in certain tumor cell lines. It is a strong pyrogen that directly acts or stimulates the secretion of interleukin-1 to cause fever. It is related to the induction of cachexia and can stimulate cell proliferation and induce cell differentiation under certain conditions. Dephosphorylation of FOXP3 impairs the function of regulatory T cells (Treg) in rheumatoid arthritis individuals. Up-regulating the expression of protein phosphatase 1 (PP1), PP1 dephosphorylates the key Ser-418 residue of FOXP3, thereby inactivating FOXP3 and deficient in Treg cell function (PubMed:23396208). In the RT4v6 bladder cancer cell line, bcg-stimulated neutrophils combined with DIABLO/SMAC mimics are key mediators of cell death in the anticancer effect (PubMed:22517918, PubMed:16829952, PubMed:23396208). By inhibiting insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake, it induces insulin resistance in adipocytes. Induces the degradation of GKAP42 protein in adipocytes, which is partly involved in tnf-induced insulin resistance (similar). 2. The formation of TNF intracellular domain (ICD) can induce dendritic cells to produce IL12.

Cancer antibody; Cell Biology and Cellular Response antibody; Immune System antibody; Metabolism antibody; Signaling Transduction antibody

1.The soluble form derives from the membrane form by proteolytic processing. The membrane-bound form is further proteolytically processed by SPPL2A or SPPL2B through regulated intramembrane proteolysis producing TNF intracellular domains (ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space. 2.The membrane form, but not the soluble form, is phosphorylated on serine residues. Dephosphorylation of the membrane form occurs by binding to soluble TNFRSF1A/TNFR1. 3.O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Infliximab

Mouse

Human

Infliximab is a chimeric monoclonal IgG1 antibody that specifically targets tumor necrosis factor (TNF-α or TNF-α). Infliximab was used for the treatment of various inflammatory diseases, such as chronic Crohn's disease in adults or children, ulcerative colitis in adults or children, rheumatoid arthritis and methotrexate , Ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Ankylosing Spondylitis (AS)
Crohn's Disease (CD)
Psoriasis Vulgaris (Plaque Psoriasis)
Psoriatic Arthritis
Rheumatoid Arthritis
Ulcerative Colitis

infliximab-axxq, infliximab-qbtx, infliximab-abda, infliximab-dyyb

Infliximab is a chimeric gG1κ monoclonal antibody that binds to soluble and transmembrane forms of TNF-α with high affinity, thereby blocking proinflammatory cascade signaling. Binding of the antibody to TNF-α prevents TNF-α from interacting with its receptor. Tumor necrosis factor-α (TNF-α) is a key pro-inflammatory cytokine involved in chronic inflammatory diseases. Its excessive activity and enhanced signaling pathways can be observed in inflammatory diseases and activate further pro-inflammatory cascades. By mediating ADCC and CDC effects, infliximab may also lead to lysis of TNF-α1 producing cells.

Ankylosing Spondylitis (AS)
Crohn's Disease (CD)
Psoriasis Vulgaris (Plaque Psoriasis)
Psoriatic Arthritis
Rheumatoid Arthritis
Ulcerative Colitis